tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A
. 2024 Jul 16;121(29):e2310421121.
doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8. Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays
Zhe Hu[SUP] 1 [/SUP], Alberto Domingo López-Muñoz[SUP] 1 [/SUP], Ivan Kosik[SUP] 1 [/SUP], Tiansheng Li[SUP] 1 [/SUP], Victoria Callahan[SUP] 2 [/SUP], Kelsie Brooks[SUP] 3 [/SUP], Debra S Yee[SUP] 3 [/SUP], Jaroslav Holly[SUP] 1 [/SUP], Jefferson J S Santos[SUP] 1 [/SUP], Ayslan Castro Brant[SUP] 4 [/SUP], Reed F Johnson[SUP] 5 [/SUP], Kazuyo Takeda[SUP] 6 [/SUP], Zhi-Ming Zheng[SUP] 4 [/SUP], Jason M Brenchley[SUP] 3 [/SUP], Jonathan W Yewdell[SUP] 1 [/SUP], Julie M Fox[SUP] 2 [/SUP]
Affiliations
We generated a replication-competent OC43 human seasonal coronavirus (CoV) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike in place of the native spike (rOC43-CoV2 S). This virus is highly attenuated relative to OC43 and SARS-CoV-2 in cultured cells and animals and is classified as a biosafety level 2 (BSL-2) agent by the NIH biosafety committee. Neutralization of rOC43-CoV2 S and SARS-CoV-2 by S-specific monoclonal antibodies and human sera is highly correlated, unlike recombinant vesicular stomatitis virus-CoV2 S. Single-dose immunization with rOC43-CoV2 S generates high levels of neutralizing antibodies against SARS-CoV-2 and fully protects human ACE2 transgenic mice from SARS-CoV-2 lethal challenge, despite nondetectable replication in respiratory and nonrespiratory organs. rOC43-CoV2 S induces S-specific serum and airway mucosal immunoglobulin A and IgG responses in rhesus macaques. rOC43-CoV2 S has enormous value as a BSL-2 agent to measure S-specific antibodies in the context of a bona fide CoV and is a candidate live attenuated SARS-CoV-2 mucosal vaccine that preferentially replicates in the upper airway.
Keywords: HCoV-OC43; SARS-CoV-2; coronavirus; mucosal vaccine; virus-neutralizing antibodies.
. 2024 Jul 16;121(29):e2310421121.
doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8. Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays
Zhe Hu[SUP] 1 [/SUP], Alberto Domingo López-Muñoz[SUP] 1 [/SUP], Ivan Kosik[SUP] 1 [/SUP], Tiansheng Li[SUP] 1 [/SUP], Victoria Callahan[SUP] 2 [/SUP], Kelsie Brooks[SUP] 3 [/SUP], Debra S Yee[SUP] 3 [/SUP], Jaroslav Holly[SUP] 1 [/SUP], Jefferson J S Santos[SUP] 1 [/SUP], Ayslan Castro Brant[SUP] 4 [/SUP], Reed F Johnson[SUP] 5 [/SUP], Kazuyo Takeda[SUP] 6 [/SUP], Zhi-Ming Zheng[SUP] 4 [/SUP], Jason M Brenchley[SUP] 3 [/SUP], Jonathan W Yewdell[SUP] 1 [/SUP], Julie M Fox[SUP] 2 [/SUP]
Affiliations
- PMID: 38976733
- DOI: 10.1073/pnas.2310421121
We generated a replication-competent OC43 human seasonal coronavirus (CoV) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike in place of the native spike (rOC43-CoV2 S). This virus is highly attenuated relative to OC43 and SARS-CoV-2 in cultured cells and animals and is classified as a biosafety level 2 (BSL-2) agent by the NIH biosafety committee. Neutralization of rOC43-CoV2 S and SARS-CoV-2 by S-specific monoclonal antibodies and human sera is highly correlated, unlike recombinant vesicular stomatitis virus-CoV2 S. Single-dose immunization with rOC43-CoV2 S generates high levels of neutralizing antibodies against SARS-CoV-2 and fully protects human ACE2 transgenic mice from SARS-CoV-2 lethal challenge, despite nondetectable replication in respiratory and nonrespiratory organs. rOC43-CoV2 S induces S-specific serum and airway mucosal immunoglobulin A and IgG responses in rhesus macaques. rOC43-CoV2 S has enormous value as a BSL-2 agent to measure S-specific antibodies in the context of a bona fide CoV and is a candidate live attenuated SARS-CoV-2 mucosal vaccine that preferentially replicates in the upper airway.
Keywords: HCoV-OC43; SARS-CoV-2; coronavirus; mucosal vaccine; virus-neutralizing antibodies.